While influenza virus diversity and antigenic drift have been well characterized on a global scale, 2 the factors that influence the virus' rapid evolution within and between human hosts are less 3 clear. Given the modest effectiveness of seasonal vaccination, vaccine-induced antibody 4 responses could serve as a potent selective pressure for novel influenza variants at the 5 individual or community level. We used next generation sequencing of patient-derived viruses 6 from a randomized, placebo-controlled trial of vaccine efficacy to characterize the diversity of 7 influenza A virus and to define the impact of vaccine-induced immunity on within-host 8 populations. Importantly, this study design allowed us to isolate the impact of vaccination while 9 still studying natural infection. We used pre-season hemagglutination inhibition and 1 0 neuraminidase inhibition titers to quantify vaccine-induced immunity directly and to assess its 1 1 impact on intrahost populations. We identified 166 cases of H3N2 influenza over 3 seasons and 1 2 5119 person-years. We obtained whole genome sequence data for 119 samples and used a 1 3 stringent and empirically validated analysis pipeline to identify intrahost single nucleotide 1 4 variants at ≥ 1% frequency. Phylogenetic analysis of consensus hemagglutinin and 1 5
individuals with influenza-like illness within 7 days of onset; residual specimen material was 1 0 5 stored in veal infusion broth (VIB) at -80°C. Viral RNA was extracted from 140µl of VIB using the 1 0 6
QIAamp viral RNA mini kit (Qiagen 52906), eluted in 50µl buffer, and stored at -80°C. Hemagglutination inhibition (HAI) and Neuraminidase agglutination inhibition (NAI) titers for 1 0 8 subjects in this study were previously measured and reported in [18, 34] . PCR master mix was thawed and stored at 4°C, 24 hours before reaction set-up. A standard 1 1 7 curve relating copy number to Ct values was generated based on 10-fold dilutions of a control 1 1 8 plasmid run in duplicate. We amplified cDNA corresponding to all 8 genomic segments from 3µl of the viral RNA using influenza A primers [35] . The thermocycler protocol was: 42°C for 60 min then 94°C for 2 min 1 2 6 then 5 cycles of 94°C for 30 sec, 44°C for 30 sec, 68°C for 3 min, then 28 cycles of 94°C for 30 1 2 7 6 sec, 57°C for 30 sec, 68°C for 3 min. Amplification of all 8 segments was confirmed by gel 1 2 8 electrophoresis, and 750ng of each cDNA mixture were sheared to an average size of 300 to 1 2 9 400bp using a Covaris S220 focused ultrasonicator. Sequencing libraries were prepared using 1 3 0 the NEBNext Ultra DNA library prep kit (NEB E7370L), Agencourt AMPure XP beads (Beckman Residual primer dimers were removed by gel isolation of a 300-500bp band, which was purified 1 3 5 using a GeneJet Gel Extraction Kit (ThermoFisher Scientific). Purified library pools were 1 3 6 sequenced on an Illumina HiSeq 2500 with 2x125 nucleotide paired end reads. All raw 1 3 7 sequence data have been deposited at the NCBI sequence read archive (BioProject submission Sequencing reads that passed standard Illumina quality control filters were binned by index and 1 4 2 aligned to the reference genome using Bowtie [36] . Single nucleotide variants (SNV) were 1 4 3 identified and analyzed using DeepSNV [37] , which relies on a clonal control to estimate the 1 4 4 local error rate within a given sequence context and to identify strand bias in base calling. The 1 4 5 clonal control was a library prepared in an identical fashion from 8 plasmids containing the 1 4 6 genome for the respective circulating reference strain and sequenced in the same flow cell to 1 4 7 control for batch effects. True positive SNV were identified from the raw output tables by 1 4 8 applying the following filtering criteria in R: (i) Bonferonni corrected p value <0.01, (ii) average MapQ score on variant reads >30, (iii) average phred score on variant positions >35, (iv) and 29 placebo. We were able to amplify and quantify genomes for 119 of the 165 influenza-1 8 9 positive samples ( Table 1 ). The average age of this sequenced cohort from all years was 24.5, 1 9 0 indicating that participants were generally young and likely shared similar influenza pre-1 9 1 exposure histories particularly after randomization. The age, sex and race of the cohort were 1 9 2 similar to that of the overall study cohort for each of the 3 seasons. In the 2007-2008 season, roughly 40% of individuals in the larger cohort reported having ever 1 9 5 received a prior influenza vaccination. Despite subject randomization, differences in pre-existing 1 9 6 immunity due to prior vaccination or influenza infection could impact results. To control for this 1 9 7 possibility, we obtained pre-season antibody titers by hemagglutination inhibition (HAI) and 1 9 8 neuraminidase inhibition (NAI) assays for all study participants against that season's vaccine individuals in the IIV group were above the geometric mean for the entire sequenced cohort, 2 0 3 LAIV subjects had titers spanning the mean, and those in the placebo group were generally 2 0 4 below the mean for all seasons. These data demonstrate that in the IIV group, and to a lesser 2 0 5 degree, the LAIV group, individuals had strain-specific antibody levels sufficient to apply 2 0 6 selective pressure against the infecting virus. We have previously shown that viral load influences the sensitivity and specificity of iSNV
. In order to determine whether viral load was different among the IIV, LAIV, and 2 1 1 placebo samples that we sequenced, we measured genome copy number by RT-qPCR for the most samples, there were no significant differences in copy number by vaccination group 2 1 4 ( Figure 1A ). In agreement with the 2007-2008 data, we did not detect differences in copy 2). Since copy number is dependent on time from illness onset [42, 43] , we analyzed the data 2 1 7 based on sample collection day ( Figure 1B ). Using days 2-4, for which there were at least 5 2 1 8 data points for each treatment group, we did not find any significant differences (p=0.24-0.57 for 2 1 9 days 2-4, non-parametric one way ANOVA). We divided the larger group of 2007-2008 subjects 2 2 0 into groups based on pre-season HAI and NAI titers ≥ 40 or <40 against that season's strain, as 2 2 1 an HAI titer of 40 is typically considered to be associated with 50% protection given exposure 2 2 2 [18, 19, 44] . This cutoff was identical to the HAI and NAI geometric mean titers for our sequenced 2 2 3 cohort (61.9 and 34.5, respectively), given the dilutions used. We did not detect differences in 2 2 4 copy number based on HAI or NAI titer ( Figure 1C-D ( Supplementary Table 1 ). We have found that the number of false positive iSNV calls is much 2 3 5 higher in samples with genome copy numbers <10 3 per µl of transport media; therefore, we only phylogenetic trees. We therefore analyzed HA and NA consensus sequences from all 87 we found that sequences from individuals in each treatment group (e.g. IIV, LAIV, or placebo)
were dispersed throughout the tree. More importantly, we found no evidence for clustering 2 5 1 based on pre-season HAI and NAI titer (by colors in Figure 2 ). We obtained similar results from 12 Some have suggested that vaccine-induced immunity will select for novel antigenic variants 2 8 3 within hosts [21] . We therefore compared iSNV in the HA gene by vaccination group and 2 8 4 serostatus. Of the 17 variants we identified that resulted in nonsynonymous changes within HA, 2 8 5 11 were in HA1 and 6 were in HA2 ( Figure 5 , Supplementary Table 3 ). Five antigenic sites, of the HA1 variants identified in our study were located in antigenic sites C and D ( Figure 5B ), 2 8 8 one of which was found in two samples ( Supplementary Table 3 ). Of these potential antigenic 2 8 9
variants, three were found in vaccinated individuals (1 IIV, 2 LAIV) and four were found in those 2 9 0 in the placebo group. When grouped by HAI titer, four were found in samples from individuals 2 9 1 with titers ≥ 40, while three were found in individuals with titers <40. No variants were specific to 2 9 2 vaccinated individuals, and antigenic diversity was similar across all groups. None of the 2 9 3
identified mutations were observed in subsequent circulating H3N2 strains. We set out to define the relationship between vaccine-induced immunity and the intrahost 2 9 7 diversity of influenza virus. We hypothesized that non-sterilizing immunity could potentially 2 9 8 select for novel antigenic variants and contribute to larger scale patterns of influenza evolution.
9 9
We were able to definitively address these questions using samples derived from a randomized, studies. In this exhaustive and well-controlled study, we found no differences in intrahost 3 0 9
influenza diversity based on vaccination status or HAI and NAI titers. in contrast with a study of experimentally-infected dogs that uncovered differences in intrahost We did not detect phylogenetic clustering of HA and NA sequences based on vaccination status, status in a case test-negative study of vaccine effectiveness [21] . Together, these data suggest 3 2 7 that vaccinated and unvaccinated individuals are infected with similar strains and that within 3 2 8 season antigenic drift is not a major contributor to reduced vaccine efficacy. Because we also 3 2 9 stratified our analysis by pre-season HAI and NAI titer, we can similarly exclude viral escape 3 3 0 from a non-sterilizing antibody response. Our data further suggest that pre-existing antibody 3 3 1 against circulating strains does not apply sufficiently strong selective pressure to drive the 3 3 2 emergence of antigenically distinct strains within a given host. High intrahost diversity may be an important factor in viral evolution, since it increases the 3 3 5 number of novel variants on which natural selection can act. Some have proposed that the 3 3 6
intrahost diversity of RNA viruses is linked to virulence [27, 28] , suggesting that processes that 3 3 7 act to restrict or enhance intrahost diversity may alter disease phenotypes. We found that within NA. Furthermore, there were no significant differences in diversity when samples were grouped 3 4 3 by HAI and NAI titer, and we did not find evidence of treatment-specific iSNV. Together our data 3 4 4
suggest that vaccine-induced immunity does not significantly influence intrahost diversity and is While the number of iSNV was similar in all groups, we considered it possible that partial apart the role of vaccination on influenza evolution. We did find a number of variants in antigenic 3 5 6 sites, but these were no more frequent than in other regions of the genome and did not vary with vaccination status or HAI and NAI titer. Importantly, our results are in conflict with earlier presence of sub-neutralizing antibody or in experimentally infected animals [24, 25, [49] [50] [51] . This sample set cannot discern whether there are differences in evolutionary pressure based on individual over the course of their infection. However, we did not observe significant differences variants is likely to be a rare event when studied at this scale. Given that our data are derived We evaluated the potential for vaccine-induced immunity to drive intrahost evolution, as this is 4 0 1 an important issue in light of the current recommendation for universal influenza vaccination.
0 2
We did not find evidence for vaccine-induced pressure on the intrahost or consensus level, 4 0 3 despite employing several methods used to study evolutionary processes. Our study is larger 4 0 4 than other reports and involves extensive analysis of both placebo and vaccination groups. Med. 1956;103: 413-424. titer. There were no differences among any of the groups by one-way ANOVA with Bonferroni 
